子宫肌瘤治疗药物市场－全球产业规模、份额、趋势、机会和预测（按药物类别、类型、最终用户、地区和竞争情况细分，2020-2030 年）

2024 年全球子宫肌瘤治疗药物市场价值为 48.5 亿美元，预计到 2030 年将以 4.40% 的年复合成长率(CAGR) 稳步增长。

市场扩张受到多种关键因素的推动，包括子宫肌瘤在全球范围内的患病率不断上升、对非手术治疗方案的偏好日益增加、药物研究的进步以及医疗服务的可及性不断提高。子宫肌瘤，也称为平滑肌瘤，是影响育龄妇女最常见的良性肿瘤之一，常与月经过多、骨盆腔疼痛和生育併发症有关。

认识的不断提高、诊断方法的改进以及治疗管道的扩大加速了药物治疗的采用。这在促性腺激素释放激素 (GnRH) 拮抗剂、基于黄体素的疗法和非荷尔蒙替代品的使用日益增多方面表现得尤为明显，反映了患者对非侵入性疗法而非外科手术的偏好发生了更广泛的转变。持续的药物创新、更高的监管批准率以及不断扩大的保险覆盖范围继续支持市场的积极前景，特别是在子宫肌瘤发病率激增和医疗服务改善的地区。

关键市场驱动因素

子宫肌瘤盛行率上升

主要市场挑战

长期疗效和安全性数据有限

主要市场趋势

联合疗法的出现

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：临床试验分析

第六章：全球子宫肌瘤治疗药物市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（促性腺激素释放激素 (Gnrh) 激动剂、促性腺激素释放激素 (Gnrh) 拮抗剂、黄体素释放子宫内避孕器 (Iud) 及避孕药、非荷尔蒙药物、其他）
  • 依类型（浆膜下子宫肌瘤、壁内子宫肌瘤、黏膜下子宫肌瘤、带蒂子宫肌瘤）
  • 按最终用户（医院药房、零售药房、其他）
  • 按地区
  • 按公司分类（2024）
• 产品市场图

第七章：北美子宫肌瘤治疗药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第八章：欧洲子宫肌瘤治疗药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太子宫肌瘤治疗药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第十章：南美子宫肌瘤治疗药物市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲子宫肌瘤治疗药物市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 14 章：政策与监管格局

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Myovant Sciences Ltd
• Pfizer Inc
• Abbvie Inc
• Ferring BV
• AstraZeneca
• Bayer AG
• Amring Pharmaceuticals Inc
• Watson Pharma Pvt Ltd

第 17 章：策略建议

第18章调查会社について・免责事项

Global Uterine Fibroid Treatment Drugs Market was valued at USD 4.85 billion in 2024 and is projected to register steady growth at a compound annual growth rate (CAGR) of 4.40% through 2030.

Market expansion is being driven by several key factors, including the rising global prevalence of uterine fibroids, increasing preference for non-surgical treatment options, advancements in pharmaceutical research, and greater accessibility to healthcare services. Uterine fibroids, also referred to as leiomyomas, are among the most common benign tumors affecting women of reproductive age and are often associated with heavy menstrual bleeding, pelvic pain, and fertility complications.

Growing awareness, improved diagnostic practices, and expanded access to treatment have accelerated the adoption of pharmacological therapies. This is particularly evident in the increasing use of gonadotropin-releasing hormone (GnRH) antagonists, progestin-based regimens, and non-hormonal alternatives, reflecting a broader shift in patient preference toward non-invasive therapies over surgical procedures. Ongoing drug innovations, higher regulatory approval rates, and expanding insurance coverage continue to support the market's positive outlook, especially in regions witnessing a surge in fibroid incidence and improved access to care.

Key Market Drivers

Rising Prevalence of Uterine Fibroids

The increasing global prevalence of uterine fibroids is a primary growth driver for the market. These benign pelvic tumors, although non-cancerous, are widespread among women of reproductive age. Due to their frequently asymptomatic nature, actual prevalence is likely underreported. Studies indicate a wide prevalence range from 4.5% to 68.6%, influenced by variables such as diagnostic methods, population demographics, and healthcare availability.

As the number of diagnosed cases continues to rise, so does the demand for effective pharmacological treatment. Factors such as late pregnancies, hormonal imbalances, and a global increase in obesity contribute significantly to the growing incidence of uterine fibroids. For instance, in 2022, one in every eight individuals globally was affected by obesity. Since 1990, obesity rates have more than doubled in adults and quadrupled in adolescents, with 2.5 billion adults classified as overweight, including 890 million with obesity. These health trends further amplify the burden of uterine fibroids and underscore the demand for scalable, non-invasive treatment solutions.

Key Market Challenges

Limited Long-Term Efficacy and Safety Data

While pharmaceutical treatments for uterine fibroids have demonstrated notable effectiveness in managing symptoms, concerns remain regarding their long-term safety and efficacy. Many clinical studies feature relatively short follow-up periods, limiting insights into extended use and sustained outcomes. To ensure continued patient trust and optimize treatment strategies, robust long-term clinical data is essential. Such data will help address safety concerns, inform regulatory decisions, and guide healthcare providers in making evidence-based therapeutic choices.

Key Market Trends

Emergence of Combination Therapies

The market is witnessing a growing interest in combination therapy approaches, integrating uterine fibroid drugs with minimally invasive procedures or complementary hormonal treatments. These integrated solutions offer the potential for enhanced symptom relief, improved patient outcomes, and a more personalized treatment experience.

Combination therapies are especially promising for patients with varying fibroid types, sizes, or symptoms, allowing for tailored care strategies that target fibroids through multiple mechanisms. This approach not only improves therapeutic efficacy but also reduces the likelihood of recurrence, positioning combination treatment as a compelling solution in the evolving landscape of uterine fibroid care.

Key Market Players

• Myovant Sciences Ltd
• Pfizer Inc
• Abbvie Inc
• Ferring BV
• AstraZeneca
• Bayer AG
• Amring Pharmaceuticals Inc
• Watson Pharma Pvt Ltd

Report Scope:

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Fibroid Treatment Drugs Market, By Drug Class:

• Gonadotropin-Releasing Hormone (Gnrh) Agonists
• Gonadotropin-Releasing Hormone (Gnrh) Antagonists
• Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
• Non-Hormonal Medications
• Others

Uterine Fibroid Treatment Drugs Market, By Type:

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Uterine Fibroid Treatment Drugs Market, By region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Uterine Fibroid Treatment Drugs Market.

Available Customizations:

Global Uterine Fibroid Treatment Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Application
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Uterine Fibroid Treatment Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
  • 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
  • 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
  • 6.2.4. By Region
  • 6.2.5. By Company (2024)
• 6.3. Product Market Map

7. North America Uterine Fibroid Treatment Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End User

8. Europe Uterine Fibroid Treatment Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End User
  • 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End User

9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End User
  • 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End User
  • 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Type
      • 9.3.4.2.3. By End User
  • 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Drug Class
      • 9.3.5.2.2. By Type
      • 9.3.5.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End User

11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Class
  • 11.2.2. By Type
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Class
      • 11.3.1.2.2. By Type
      • 11.3.1.2.3. By End User
  • 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Class
      • 11.3.2.2.2. By Type
      • 11.3.2.2.3. By End User
  • 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Class
      • 11.3.3.2.2. By Type
      • 11.3.3.2.3. By End User
  • 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Drug Class
      • 11.3.4.2.2. By Type
      • 11.3.4.2.3. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Policy & Regulatory Landscape

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. Competitive Landscape

• 16.1. Myovant Sciences Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Product & Service Offerings
  • 16.1.3. Recent Developments
  • 16.1.4. Financials (If Listed)
  • 16.1.5. Key Personnel
  • 16.1.6. SWOT Analysis
• 16.2. Pfizer Inc
• 16.3. Abbvie Inc
• 16.4. Ferring BV
• 16.5. AstraZeneca
• 16.6. Bayer AG
• 16.7. Amring Pharmaceuticals Inc
• 16.8. Watson Pharma Pvt Ltd

17. Strategic Recommendations

18. About Us & Disclaimer